Eli Lilly and Company (NYSE:LLY) Stock Holdings Reduced by Cyrus J. Lawrence LLC

Cyrus J. Lawrence LLC lessened its holdings in Eli Lilly and Company (NYSE:LLY) by 0.1% in the 2nd quarter, Holdings Channel.com reports. The firm owned 21,251 shares of the company’s stock after selling 25 shares during the quarter. Eli Lilly and Company makes up about 3.9% of Cyrus J. Lawrence LLC’s holdings, making the stock its 5th largest holding. Cyrus J. Lawrence LLC’s holdings in Eli Lilly and Company were worth $19,240,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of LLY. Core Wealth Advisors Inc. raised its position in shares of Eli Lilly and Company by 188.2% in the 4th quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock worth $29,000 after acquiring an additional 32 shares in the last quarter. Lynx Investment Advisory bought a new position in Eli Lilly and Company in the second quarter worth about $32,000. LGT Financial Advisors LLC purchased a new stake in shares of Eli Lilly and Company during the second quarter valued at about $36,000. Frank Rimerman Advisors LLC bought a new stake in shares of Eli Lilly and Company in the 4th quarter valued at about $37,000. Finally, Redmont Wealth Advisors LLC purchased a new position in shares of Eli Lilly and Company in the 1st quarter worth approximately $40,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Insider Buying and Selling

In other news, major shareholder Lilly Endowment Inc sold 58,749 shares of the business’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $915.26, for a total transaction of $53,770,609.74. Following the completion of the sale, the insider now owns 97,308,620 shares of the company’s stock, valued at $89,062,687,541.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last quarter, insiders sold 425,000 shares of company stock valued at $394,455,351. 0.13% of the stock is owned by corporate insiders.

Eli Lilly and Company Stock Performance

Shares of NYSE LLY opened at $921.49 on Monday. The company has a market capitalization of $875.79 billion, a PE ratio of 135.71, a price-to-earnings-growth ratio of 2.79 and a beta of 0.42. The company has a debt-to-equity ratio of 1.74, a quick ratio of 0.87 and a current ratio of 1.11. The company’s fifty day moving average price is $895.06 and its 200 day moving average price is $838.73. Eli Lilly and Company has a 1 year low of $516.57 and a 1 year high of $972.53.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, beating the consensus estimate of $2.64 by $1.28. The firm had revenue of $11.30 billion during the quarter, compared to analyst estimates of $9.83 billion. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. On average, research analysts predict that Eli Lilly and Company will post 16.49 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on LLY shares. Cantor Fitzgerald reissued an “overweight” rating and set a $885.00 target price on shares of Eli Lilly and Company in a research report on Monday, September 16th. Evercore ISI raised Eli Lilly and Company to a “hold” rating in a research report on Thursday, September 5th. Bank of America boosted their target price on Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Wells Fargo & Company increased their price target on Eli Lilly and Company from $875.00 to $1,000.00 and gave the company an “overweight” rating in a research note on Friday, August 9th. Finally, Jefferies Financial Group raised their price target on Eli Lilly and Company from $994.00 to $1,015.00 and gave the stock a “buy” rating in a report on Monday, June 24th. Three investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. Based on data from MarketBeat.com, Eli Lilly and Company has a consensus rating of “Moderate Buy” and an average target price of $977.35.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.